These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 28883001)

  • 61. TACH101, a first-in-class pan-inhibitor of KDM4 histone demethylase.
    Chandhasin C; Dang V; Perabo F; Del Rosario J; Chen YK; Filvaroff E; Stafford JA; Clarke M
    Anticancer Drugs; 2023 Nov; 34(10):1122-1131. PubMed ID: 37067993
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Structure-based design and discovery of potent and selective KDM5 inhibitors.
    Nie Z; Shi L; Lai C; O'Connell SM; Xu J; Stansfield RK; Hosfield DJ; Veal JM; Stafford JA
    Bioorg Med Chem Lett; 2018 May; 28(9):1490-1494. PubMed ID: 29627262
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Chemotherapeutic Stress Influences Epithelial-Mesenchymal Transition and Stemness in Cancer Stem Cells of Triple-Negative Breast Cancer.
    Li X; Strietz J; Bleilevens A; Stickeler E; Maurer J
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31936348
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Harnessing stemness and PD-L1 expression by AT-rich interaction domain-containing protein 3B in colorectal cancer.
    Liao TT; Lin CC; Jiang JK; Yang SH; Teng HW; Yang MH
    Theranostics; 2020; 10(14):6095-6112. PubMed ID: 32483441
    [No Abstract]   [Full Text] [Related]  

  • 65. Recent Advances with KDM4 Inhibitors and Potential Applications.
    Wu Q; Young B; Wang Y; Davidoff AM; Rankovic Z; Yang J
    J Med Chem; 2022 Jul; 65(14):9564-9579. PubMed ID: 35838529
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Silencing the epigenetic silencer KDM4A for TRAIL and DR5 simultaneous induction and antitumor therapy.
    Wang J; Wang H; Wang LY; Cai D; Duan Z; Zhang Y; Chen P; Zou JX; Xu J; Chen X; Kung HJ; Chen HW
    Cell Death Differ; 2016 Nov; 23(11):1886-1896. PubMed ID: 27612013
    [TBL] [Abstract][Full Text] [Related]  

  • 67. SET Domain-Containing Protein 4 Epigenetically Controls Breast Cancer Stem Cell Quiescence.
    Ye S; Ding YF; Jia WH; Liu XL; Feng JY; Zhu Q; Cai SL; Yang YS; Lu QY; Huang XT; Yang JS; Jia SN; Ding GP; Wang YH; Zhou JJ; Chen YD; Yang WJ
    Cancer Res; 2019 Sep; 79(18):4729-4743. PubMed ID: 31308046
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Long non-coding RNA NEAT1 confers oncogenic role in triple-negative breast cancer through modulating chemoresistance and cancer stemness.
    Shin VY; Chen J; Cheuk IW; Siu MT; Ho CW; Wang X; Jin H; Kwong A
    Cell Death Dis; 2019 Mar; 10(4):270. PubMed ID: 30894512
    [TBL] [Abstract][Full Text] [Related]  

  • 69. JMJD1C-mediated metabolic dysregulation contributes to HOXA9-dependent leukemogenesis.
    Lynch JR; Salik B; Connerty P; Vick B; Leung H; Pijning A; Jeremias I; Spiekermann K; Trahair T; Liu T; Haber M; Norris MD; Woo AJ; Hogg P; Wang J; Wang JY
    Leukemia; 2019 Jun; 33(6):1400-1410. PubMed ID: 30622285
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Optimizing poly (ADP-ribose) polymerase inhibition through combined epigenetic and immunotherapy.
    Prasanna T; Wu F; Khanna KK; Yip D; Malik L; Dahlstrom JE; Rao S
    Cancer Sci; 2018 Nov; 109(11):3383-3392. PubMed ID: 30230653
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Erythropoietin activates cell survival pathways in breast cancer stem-like cells to protect them from chemotherapy.
    Todaro M; Turdo A; Bartucci M; Iovino F; Dattilo R; Biffoni M; Stassi G; Federici G; De Maria R; Zeuner A
    Cancer Res; 2013 Nov; 73(21):6393-400. PubMed ID: 24008319
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Dasatinib sensitises triple negative breast cancer cells to chemotherapy by targeting breast cancer stem cells.
    Tian J; Raffa FA; Dai M; Moamer A; Khadang B; Hachim IY; Bakdounes K; Ali S; Jean-Claude B; Lebrun JJ
    Br J Cancer; 2018 Dec; 119(12):1495-1507. PubMed ID: 30482914
    [TBL] [Abstract][Full Text] [Related]  

  • 73. miR-155 increases stemness and decitabine resistance in triple-negative breast cancer cells by inhibiting TSPAN5.
    Yang LW; Wu XJ; Liang Y; Ye GQ; Che YC; Wu XZ; Zhu XJ; Fan HL; Fan XP; Xu JF
    Mol Carcinog; 2020 Apr; 59(4):447-461. PubMed ID: 32096299
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Transcriptional profiles of different states of cancer stem cells in triple-negative breast cancer.
    Liu M; Liu Y; Deng L; Wang D; He X; Zhou L; Wicha MS; Bai F; Liu S
    Mol Cancer; 2018 Feb; 17(1):65. PubMed ID: 29471829
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Modulation of SOX2 expression delineates an end-point for paclitaxel-effectiveness in breast cancer stem cells.
    Mukherjee P; Gupta A; Chattopadhyay D; Chatterji U
    Sci Rep; 2017 Aug; 7(1):9170. PubMed ID: 28835684
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Inhibitor scaffold for the histone lysine demethylase KDM4C (JMJD2C).
    Leurs U; Clausen RP; Kristensen JL; Lohse B
    Bioorg Med Chem Lett; 2012 Sep; 22(18):5811-3. PubMed ID: 22917519
    [TBL] [Abstract][Full Text] [Related]  

  • 77. FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells.
    Hamurcu Z; Ashour A; Kahraman N; Ozpolat B
    Oncotarget; 2016 Mar; 7(13):16619-35. PubMed ID: 26918606
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Interferon-beta represses cancer stem cell properties in triple-negative breast cancer.
    Doherty MR; Cheon H; Junk DJ; Vinayak S; Varadan V; Telli ML; Ford JM; Stark GR; Jackson MW
    Proc Natl Acad Sci U S A; 2017 Dec; 114(52):13792-13797. PubMed ID: 29229854
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Jmjd2/Kdm4 demethylases are required for expression of Il3ra and survival of acute myeloid leukemia cells.
    Agger K; Miyagi S; Pedersen MT; Kooistra SM; Johansen JV; Helin K
    Genes Dev; 2016 Jun; 30(11):1278-88. PubMed ID: 27257215
    [TBL] [Abstract][Full Text] [Related]  

  • 80. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
    Blanchard Z; Paul BT; Craft B; ElShamy WM
    Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.